Brands target GLP‑1 diets

Food companies are starting to build products around people taking GLP-1 weight-loss drugs, turning a prescription trend into a new food category. (arlafoodsingredients.com) Arla Foods Ingredients said on April 15 that it will show GLP-1 “companion nutrition” concepts at Vitafoods Europe in Barcelona from May 5 to May 7, 2026. The lineup is aimed at users with smaller appetites and includes high-protein dairy and water-based products. (arlafoodsingredients.com; vitafoods.eu.com) The company’s examples are tightly portioned: a 70-milliliter fermented shot with 10 grams of protein, a 200-milliliter drinking yogurt with 20 grams, a 120-gram spoonable yogurt with 20 grams, and a 100-milliliter water-based shot with 21 grams. Arla said the products use its Nutrilac and Lacprodan proteins and cultures from Novonesis to support muscle health and digestion. (arlafoodsingredients.com) GLP-1 drugs slow digestion and reduce appetite, which helps people eat less but can also make it harder to get enough protein and calories from regular meals. A 2025 joint advisory from four U.S. medical and nutrition groups said treatment can bring gastrointestinal side effects, nutritional deficiencies from calorie reduction, and muscle and bone loss without broader nutrition support. (pmc.ncbi.nlm.nih.gov) That has given ingredient makers a simple pitch to food brands: sell smaller servings that pack in more protein, calcium, and other nutrients. Arla cited research saying 11% of consumers trying to lose weight globally in 2025 and 18% in the United States reported using GLP-1 drugs. (arlafoodsingredients.com) The market is also shifting because the drugs themselves are becoming easier to get in standard forms. Novo Nordisk said the U.S. Food and Drug Administration approved a once-daily Wegovy pill on December 22, 2025, adding an oral option to a market previously dominated by injections. (drugs.com; accessdata.fda.gov) At the same time, regulators are tightening the rules around copycat versions. The Food and Drug Administration said on April 1, 2026, that compounded products can be treated as “essentially a copy” of a commercially available drug if they use the same active ingredient in the same or similar strength and route of administration, with limited exceptions for documented patient-specific differences. (fda.gov) For food and supplement companies, the opening is not to sell the drug but to sell the routine around it: breakfast shots, drinkable yogurts, and medical-nutrition formats that fit reduced appetites. Arla’s pitch in Barcelona is that the next GLP-1 product boom may sit in the refrigerated aisle, not the pharmacy fridge. (foodanddrinktechnology.com; arlafoodsingredients.com)